



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Suthat Liangpunsakul, MD, MPH

Committee: Pharmacy Compounding Advisory Committee (ODAC)

Meeting Date: June 9, 2021

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On June 9, 2021, the committee will discuss choline chloride, a bulk drug substance, nominated for inclusion on the 503A Bulk List – evaluated for use in liver diseases (including non-alcoholic fatty liver disease), hepatic steatosis, atherosclerosis, fetal alcohol spectrum disorder, and supplementation in long term total parenteral nutrition.

Table with 3 columns: Type of Interest, Nature, Magnitude. Row 1: I. Personal/Immediate Family. Row 2: Stocks/investments, (b) (6) healthcare sector mutual fund a, \$250,000 - 350,000. Row 3: II. Other Imputed Interests. Row 4: None.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/s/ Signature

05/20/2021 Date